NuVision Biotherapies (NuVision) is a Nottingham based spin out from the Faculty of Medicine at the University of Nottingham.

Dr Andrew Hopkinson incorporated the company in 2015 having spent 15 years researching the properties of amniotic membrane, which is now the foundation of the patented Tereo® manufacture process used in all of NuVision’s products. Nu-Vision commercialise high quality and affordable bio therapies for treating ‘front of the eye’ disease and trauma. Omnigen is currently the first UK dry human amnion derived product to have delivered proof of concept, and is now being used in over 60 UK hospitals, 14 different countries and delivering 6000 sight saving treatments for patients.